Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan + Chlorthalidone in Essential Hypertension
NCT02521233Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
A Phase 3 trial of candesartan cilexetil, chlorthalidone in essential hypertension, sponsored by EMS. Planned start Nov 2016; status: withdrawn.
02
Drugs
candesartan cilexetilchlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02521233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521233.